Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness and Handling of Spiolto® Respimat ® in COPD Patients - Italy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~1. Written informed consent prior to participation~2. Female and male patients = 40 years of age~3. Patients diagnosed with COPD and requiring long-acting dual bronchodilation (LAMA + LABA) treatment according to approved Spiolto® Respimat® SmPC and therapeutic plan recommendation~Exclusion criteria:~1. Patients with contraindications according to Spiolto® Respimat® Summary of Product Characteristics (SmPC)~2. Patients who have been treated with a LABA/LAMA combination (free and fixed dose) in the previous 6 months~3. Patients continuing LABA-Inhalative Corticosteroids (ICS) treatment should not be additionally treated with Spiolto® Respimat® in order to avoid a double dosing of long-acting beta-agonists~4. Patients for whom further follow-up is not possible at the enrolling site during the planned study period of approx. 6 weeks~5. Pregnancy and lactation~6. Patients currently listed for lung transplantation~7. Current participation in any clinical trial or any other non-interventional study of a drug or device

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Spiolto® Respimat® (Type: None): consented COPD patients who will be treated with Spiolto® Respimat® according to the approved SmPC

Based on this trial design, predict the completion outcome and termination type (if applicable).